JP2010500371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500371A5 JP2010500371A5 JP2009523968A JP2009523968A JP2010500371A5 JP 2010500371 A5 JP2010500371 A5 JP 2010500371A5 JP 2009523968 A JP2009523968 A JP 2009523968A JP 2009523968 A JP2009523968 A JP 2009523968A JP 2010500371 A5 JP2010500371 A5 JP 2010500371A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- pharmaceutical composition
- pharmaceutical combination
- huluc63
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83618506P | 2006-08-07 | 2006-08-07 | |
| US60/836,185 | 2006-08-07 | ||
| US94426207P | 2007-06-15 | 2007-06-15 | |
| US60/944,262 | 2007-06-15 | ||
| PCT/US2007/075403 WO2008019378A1 (en) | 2006-08-07 | 2007-08-07 | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500371A JP2010500371A (ja) | 2010-01-07 |
| JP2010500371A5 true JP2010500371A5 (enExample) | 2010-10-07 |
| JP5340935B2 JP5340935B2 (ja) | 2013-11-13 |
Family
ID=38831279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523968A Active JP5340935B2 (ja) | 2006-08-07 | 2007-08-07 | 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US8632772B2 (enExample) |
| EP (5) | EP2641601B8 (enExample) |
| JP (1) | JP5340935B2 (enExample) |
| CN (1) | CN101686971B (enExample) |
| AU (1) | AU2007281684C1 (enExample) |
| BR (1) | BRPI0716647A2 (enExample) |
| CA (1) | CA2660356C (enExample) |
| CY (5) | CY1116247T1 (enExample) |
| DK (2) | DK2641601T3 (enExample) |
| ES (2) | ES2535437T3 (enExample) |
| HR (2) | HRP20150449T1 (enExample) |
| HU (4) | HUE029027T2 (enExample) |
| IL (2) | IL196919A (enExample) |
| LT (4) | LT2641601T (enExample) |
| LU (3) | LU93277I2 (enExample) |
| MX (1) | MX2009001441A (enExample) |
| NL (1) | NL300840I2 (enExample) |
| NO (1) | NO346835B1 (enExample) |
| NZ (1) | NZ574978A (enExample) |
| PL (2) | PL2641601T3 (enExample) |
| PT (2) | PT2068874E (enExample) |
| SI (2) | SI2068874T1 (enExample) |
| WO (1) | WO2008019378A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2068874E (pt) | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| CN102112147B (zh) | 2008-06-02 | 2014-05-21 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138、和cs1肽 |
| KR20110028450A (ko) | 2008-06-16 | 2011-03-18 | 이뮤노젠 아이엔씨 | 새로운 상승 효과 |
| EA024364B1 (ru) * | 2008-10-21 | 2016-09-30 | Оникс Терапьютикс, Инк. | Способ лечения множественной миеломы |
| ES2502541T3 (es) | 2009-09-10 | 2014-10-03 | Kyowa Hakko Kirin Co., Ltd. | Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4) |
| CA2780998C (en) * | 2009-11-24 | 2016-07-12 | Celgene Corporation | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells |
| CN102241773B (zh) * | 2010-05-13 | 2014-05-14 | 四川大学 | 抗骨髓瘤细胞多克隆抗体及其制备方法 |
| AU2013337247B2 (en) | 2012-11-05 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| ES2707057T3 (es) * | 2013-11-06 | 2019-04-02 | Bristol Myers Squibb Co | Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple |
| US20160264670A1 (en) | 2013-11-06 | 2016-09-15 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2015075011A1 (en) * | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
| SMT202300081T1 (it) * | 2014-08-22 | 2023-05-12 | Celgene Corp | Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi |
| WO2016049022A1 (en) * | 2014-09-23 | 2016-03-31 | Board Of Trustees Of Michigan State University | Compositions and methods for modulating an immune response |
| US10365280B2 (en) | 2014-10-02 | 2019-07-30 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating malignancies |
| JP2017537893A (ja) | 2014-10-31 | 2017-12-21 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗ｃｓ１抗体および抗体薬結合体 |
| US10302644B2 (en) | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
| US20170355768A1 (en) * | 2014-12-04 | 2017-12-14 | Bristol-Myers Squibb Company | Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma) |
| PL3294769T3 (pl) | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
| PL3313528T3 (pl) | 2015-06-29 | 2021-12-13 | Bristol-Myers Squibb Company | Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka |
| CN109498799A (zh) * | 2016-03-13 | 2019-03-22 | 曹帅 | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 |
| US11124579B2 (en) | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| CN111373246A (zh) * | 2017-11-22 | 2020-07-03 | 希成生物医药 | 包括硼替佐米的聚合物纳米颗粒 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| JP2022553821A (ja) | 2019-11-05 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍ－タンパク質アッセイおよびその使用 |
| CN115368462B (zh) * | 2022-07-19 | 2026-01-02 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| JPH11511746A (ja) | 1995-05-25 | 1999-10-12 | バクスター、インターナショナル、インコーポレイテッド | 同種幹細胞移植後の癌の同種細胞治療 |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CN1981761B (zh) * | 2002-05-17 | 2011-10-12 | 细胞基因公司 | 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物 |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| AU2005302083A1 (en) * | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of B-cell malignancies |
| JP2010500370A (ja) | 2006-08-07 | 2010-01-07 | ピーディーエル バイオファーマ，インコーポレイティド | 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法 |
| EP2069478A2 (en) | 2006-08-07 | 2009-06-17 | PDL BioPharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| PT2068874E (pt) | 2006-08-07 | 2015-05-21 | Abbvie Biotherapeutics Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-csi |
-
2007
- 2007-08-07 PT PT78407467T patent/PT2068874E/pt unknown
- 2007-08-07 EP EP13168383.1A patent/EP2641601B8/en active Active
- 2007-08-07 AU AU2007281684A patent/AU2007281684C1/en active Active
- 2007-08-07 PL PL13168383T patent/PL2641601T3/pl unknown
- 2007-08-07 JP JP2009523968A patent/JP5340935B2/ja active Active
- 2007-08-07 ES ES07840746.7T patent/ES2535437T3/es active Active
- 2007-08-07 EP EP07840746.7A patent/EP2068874B1/en active Active
- 2007-08-07 CA CA2660356A patent/CA2660356C/en active Active
- 2007-08-07 PL PL07840746T patent/PL2068874T3/pl unknown
- 2007-08-07 SI SI200731641T patent/SI2068874T1/sl unknown
- 2007-08-07 EP EP15152731.4A patent/EP2942057A1/en not_active Withdrawn
- 2007-08-07 DK DK13168383.1T patent/DK2641601T3/en active
- 2007-08-07 MX MX2009001441A patent/MX2009001441A/es active IP Right Grant
- 2007-08-07 US US11/835,257 patent/US8632772B2/en active Active
- 2007-08-07 CN CN200780033988XA patent/CN101686971B/zh active Active
- 2007-08-07 PT PT131683831T patent/PT2641601T/pt unknown
- 2007-08-07 ES ES13168383.1T patent/ES2589302T3/es active Active
- 2007-08-07 EP EP13168364.1A patent/EP2641600A1/en not_active Withdrawn
- 2007-08-07 HU HUE13168383A patent/HUE029027T2/en unknown
- 2007-08-07 NO NO20090968A patent/NO346835B1/no unknown
- 2007-08-07 BR BRPI0716647A patent/BRPI0716647A2/pt not_active Application Discontinuation
- 2007-08-07 DK DK07840746T patent/DK2068874T3/da active
- 2007-08-07 SI SI200731803A patent/SI2641601T1/sl unknown
- 2007-08-07 NZ NZ574978A patent/NZ574978A/xx unknown
- 2007-08-07 LT LTEP13168383.1T patent/LT2641601T/lt unknown
- 2007-08-07 HR HRP20150449TT patent/HRP20150449T1/hr unknown
- 2007-08-07 EP EP16169025.0A patent/EP3115049A1/en not_active Withdrawn
- 2007-08-07 WO PCT/US2007/075403 patent/WO2008019378A1/en not_active Ceased
-
2009
- 2009-02-05 IL IL196919A patent/IL196919A/en active Protection Beyond IP Right Term
-
2013
- 2013-12-23 US US14/139,096 patent/US20140322201A1/en not_active Abandoned
-
2015
- 2015-04-24 CY CY20151100379T patent/CY1116247T1/el unknown
- 2015-08-24 US US14/834,077 patent/US20160137735A1/en not_active Abandoned
-
2016
- 2016-02-03 IL IL243933A patent/IL243933A0/en unknown
- 2016-08-18 CY CY20161100817T patent/CY1117992T1/el unknown
- 2016-10-06 HR HRP20161284TT patent/HRP20161284T1/hr unknown
- 2016-10-20 HU HUS1600044C patent/HUS1600044I1/hu unknown
- 2016-10-20 HU HUS1600043C patent/HUS1600043I1/hu unknown
- 2016-10-20 HU HUS1600045C patent/HUS1600045I1/hu unknown
- 2016-10-24 LU LU93277C patent/LU93277I2/fr unknown
- 2016-10-24 LU LU93275C patent/LU93275I2/fr unknown
- 2016-10-24 LU LU93276C patent/LU93276I2/fr unknown
- 2016-10-25 NL NL300840C patent/NL300840I2/nl unknown
- 2016-10-26 CY CY2016037C patent/CY2016037I1/el unknown
- 2016-10-26 CY CY2016036C patent/CY2016036I1/el unknown
- 2016-10-26 CY CY2016038C patent/CY2016038I1/el unknown
- 2016-10-27 LT LTPA2016031C patent/LTC2068874I2/lt unknown
- 2016-10-27 LT LTPA2016029C patent/LTPA2016029I1/lt unknown
- 2016-10-27 LT LTPA2016030C patent/LTPA2016030I1/lt unknown
-
2017
- 2017-08-07 US US15/670,681 patent/US20170342150A1/en not_active Abandoned